ASCO

ASCO Posters Reflect on Reimbursement Trends, Combination Therapies Involving Biosimilars

June 24th 2024

Article

Two posters from the American Society of Clinical Oncology (ASCO) annual meeting look at Medicare reimbursement trends for originator and biosimilar biologics, as well as a combination therapy utilizing a pegfilgrastim biosimilar in patients with advanced hepatocellular carcinoma.

New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers

June 11th 2024

Article

Posters from the American Society of Clinical Oncology annual meeting showcased safety and efficacy data for a trastuzumab biosimilar and an ado-trastuzumab biosimilar in HER2-positive (HER2+) cancers.

ASCO 2024 Posters Showcase Positive Data on Denosumab, Pegfilgrastim Biosimilars

June 5th 2024

Article

Posters from the American Society of Clinical Oncology (ASCO) 2024 annual meeting demonstrate positive safety and efficacy data for denosumab and pegfilgrastim biosimilars.

Abstracts Highlight Growing Comfortability With Trastuzumab Biosimilars in Breast Cancer

July 31st 2023

Article

Abstracts presented at the annual meeting of the American Society of Clinical Oncology (ASCO 2023) emphasized the safety and efficacy of a trastuzumab biosimilar in treating HER2-positive breast cancer and growing utilization of trastuzumab biosimilars over time.

Dose Rounding Can Reduce Drug Waste Costs Associated With Reference, Biosimilar Bevacizumab

June 19th 2023

Article

Implementing strategies, such as dose rounding, can offset the impact of drug waste and reduce the total cost of care for value-based programs, according to a recent study of practices participating in the Oncology Care Model.

Posters Assess Quality of Trastuzumab, Denosumab Biosimilars in Cancer

July 19th 2022

Article

Posters from the American Society of Clinical Oncology’s annual meeting showed the safety and efficacy of a trastuzumab biosimilar and a denosumab biosimilar in different types of cancer.

ASCO Studies Assess Biosimilar Substitution, Adoption in Oncology Practices

June 16th 2022

Article

Abstracts from the American Society of Clinical Oncology (ASCO) annual meeting took a look at the impact biosimilar substitution and increased biosimilar adoption had on spending within practices participating in value-based payment models and the Oncology Care Model.

ASCO Posters Reveal Successful Approaches to Biosimilar Adoption in Oncology

June 6th 2022

Article

Posters presented at the American Society of Clinical Oncology (ASCO)'s annual meeting showed the successful approaches health systems took to encourage greater adoption of oncology biosimilars.

Budget Model Predicts Savings for Switch to Rituximab Biosimilar in NHL, CLL

June 26th 2021

Article

Sizeable savings per patient with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) were anticipated by a Medicare savings model.

Poll: What Were the Most Important Biosimilar Findings Presented at ASCO?

June 23rd 2021

Article

Diverse findings on biosimilar safety and savings were presented at the American Society for Clinical Oncology (ASCO) 2021 Annual Meeting.